

Bloodstream Infections in Europe: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

Helio S. Sader, Cecilia G. Carvalhaes, Leonard R. Duncan, Dee Shortridge, Mike D. Huband, Rodrigo M. Mendes, Mariana Castanheira

JMI Laboratories, North Liberty, Iowa, USA

Objective

- To evaluate the antimicrobial susceptibility results for BSI in European medical centres.


Methods

- 8,571 organisms were consecutively collected (1/patient) as part of the SENTRY Program:
 - Western Europe (W-EU): 7,011 isolates from 26 medical centres in 10 countries: Belgium, France, Germany, Ireland, Italy, Portugal, Spain, Sweden, Switzerland, and the United Kingdom
 - Eastern Europe and Mediterranean region (E-EU): 1,560 isolates from 12 medical centres in 9 countries: Belarus, Czech Republic, Greece, Hungary, Israel, Romania, Russia, Slovenia, and Turkey
- Organisms were susceptibility tested by reference broth microdilution methods in a central laboratory.
- EUCAST breakpoints were applied.


Results

Figure 1. Frequency of occurrence

A. Western Europe



B. Eastern Europe




Abbreviations: BHS, β -haemolytic streptococci; VGS, viridans group streptococci

- *E. coli*, *S. aureus*, and *K. pneumoniae* represented the top 3 organisms in W-EU and E-EU and accounted for 55.9 and 58.3% of the collection, respectively.
- Gram-negative bacilli represented 60.7% of organisms in W-EU and 66.5% in E-EU.

Results

Figure 2. Selected susceptibility results from Western Europe and Eastern Europe



Abbreviations: CAZ-AVI, ceftazidime-avibactam; MEM-VAB, meropenem-vaborbactam; CRE, carbapenem-resistant Enterobacteriales; CRO, ceftriaxone; LEV, levofloxacin; C-T, ceftolozane-tazobactam; PIP-TAZ, piperacillin-tazobactam; OXA, oxacillin.

- CAZ-AVI and MEM-VAB were very active against Enterobacteriales from W-EU and E-EU
- CRE from E-EU: Only 59.1% S to MEM-VAB
- *E. coli*: Lower susceptibility to CRO, LEV, and other drugs in E-EU than W-EU
- *K. pneumoniae*: Only 35.8% S to CRO and 80.8% S to MEM in E-EU
- *P. aeruginosa*: Increasing resistance to CAZ-AVI, C-T, PIP-TAZ, and MEM in E-EU
- *S. aureus*: Higher MRSA rates in E-EU than W-EU
- *E. faecalis*: Very low vancomycin resistance (VRE) in both W-EU (1.6%) and E-EU (0.0%)
- *E. faecium*: VRE rates of 24.3% in W-EU and 30.9% in E-EU

Results

- Carbapenem-resistant (CRE), multidrug-resistant (MDR), and extensively drug-resistant phenotypes among *Enterobacterales* were markedly higher in E-EU compared to W-EU.

Phenotype	W-EU	E-EU
CRE	2.2%	8.6%
MDR	13.6%	30.0%
XDR	2.0%	7.3%

Conclusions

- The frequency of organisms and susceptibility rates varied considerably between W-EU and E-EU.
- Increased resistance to newer β -lactamase inhibitor combinations among CRE and *P. aeruginosa* from E-EU countries is of great concern.

Acknowledgements

This study was sponsored by JMI Laboratories, North Liberty, IA, USA.
We thank all participants of the SENTRY Program for providing isolates.

Contact

Helio S. Sader, MD, PhD helio-sader@jmilabs.com

SENTRY results are available: sentry-mvp.jmilabs.com